They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...
Pi Network remains in a deep bear market and is facing significant risks ahead of the much-anticipated Pi Day. Pi Coin (PI) dropped by over 45% from its highest level in February, bringing its market ...
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA ...
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for Dupixent to treat adults with bullous pemphigoid.
Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...
The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP. The primary endpoint was met, with five times more ...
Regeneron and Sanofi have collaborated on Dupixent since 2007. Credit: The Washington Post via Getty Images. Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another ...
This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, ...
Join Our Telegram channel to stay up to date on breaking news coverage The Pi [IOU] price surged 13% in the past 24 hours to trade at $128 as of 03:03 a.m. EST on trading volume that rose 39% to ...
The cryptocurrency world is abuzz with anticipation as Pi Network prepares for a major milestone—the long-awaited Open Mainnet launch on February 20, 2025. This transition from a closed ecosystem to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results